

| Trial | Drug (if applicable) | Patent No. | Filed Date | Petitioner(s) | Patent Owner(s) | Inst. Dec. | Outcome | Details of FWD |
|--|----------------------|------------|------------|--|--|------------|---------|----------------|
| <Information obtained primarily from Lex Machina™ and public sources on the Internet. If any errors are identified, please contact Lisa Mandrusiak at Oblon.> | | | | | | | | |
| IPR2019-00037 | | 6,596,296 | 9-Oct-18 | Medtronic, Inc.; Tyrx, Inc. | Board of Regents of the University of Texas; TissueGen, Inc. | N/A | Pending | N/A |
| IPR2019-00038 | | 7,033,603 | 9-Oct-18 | Medtronic, Inc.; Tyrx, Inc. | Board of Regents of the University of Texas; TissueGen, Inc. | N/A | Pending | N/A |
| IPR2019-00130 | | 9,598,731 | 7-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Guardant Health, Inc. | Denied | N/A | N/A |
| IPR2019-00136 | Jevtana® Kit | 5,847,170 | 31-Oct-18 | GKC PII Holdings, LLC; Burford Capital Investment Management LLC; Burford Capical Ireland DAC et al. | Aventis Pharma S.A. | Denied | N/A | N/A |
| IPR2019-00164 | | 8,880,350 | 5-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Instituted | Pending | N/A |
| IPR2019-00165 | | 9,092,392 | 6-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Denied | N/A | N/A |
| IPR2019-00166 | | 9,292,660 | 6-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Instituted | Pending | N/A |
| IPR2019-00170 | | 9,372,193 | 5-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Instituted | Pending | N/A |
| IPR2019-00171 | | 9,383,365 | 5-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Instituted | Pending | N/A |
| IPR2019-00203 | | 9,292,660 | 6-Nov-18 | Foundation Medicine, Inc.; Roche Finance Ltd.; Roche Holding Ltd.; Roche Holdings, Inc. | Caris MPI, Inc. | Instituted | Pending | N/A |

| | | | | | | | | |
|---------------|-----------|-----------|-----------|--|---|-----------------------------|---------|-----|
| IPR2019-00207 | Aczone® | 9,517,219 | 6-Nov-18 | Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC | Almirall LLC | Instituted | Pending | N/A |
| IPR2019-00230 | | 9,422,345 | 7-Nov-18 | Merck Sharp & Dohme Corp.; Merck & Co. Inc. | GlaxoSmithKline Biologicals S.A. | Instituted | Pending | N/A |
| IPR2019-00241 | | 9,422,345 | 7-Nov-18 | Merck Sharp & Dohme Corp.; Merck & Co. Inc. | GlaxoSmithKline Biologicals S.A. | Instituted | Pending | N/A |
| IPR2019-00266 | | 8,236,504 | 9-Nov-18 | Agilent Technologies, Inc. | Bio-Rad Laboratories, Inc. | Denied | N/A | N/A |
| IPR2019-00268 | | 8,835,118 | 9-Nov-18 | Agilent Technologies, Inc. | Bio-Rad Laboratories, Inc. | Denied | N/A | N/A |
| IPR2019-00271 | | 7,148,043 | 9-Nov-18 | Agilent Technologies, Inc. | Bio-Rad Laboratories, Inc. | Instituted | Pending | N/A |
| IPR2019-00313 | | 9,776,941 | 12-Nov-18 | Celanese International Corporation | Daicel Corporation | Settled pre- institution | N/A | N/A |
| IPR2019-00328 | Suboxone® | 9,687,454 | 13-Nov-18 | Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc. | Indivior UK Limited | Denied | N/A | N/A |
| IPR2019-00329 | Suboxone® | 9,687,454 | 13-Nov-18 | Dr. Reddy's Laboratories S.A. and Dr. Reddy's Laboratories, Inc. | Indivior UK Limited | Instituted | Pending | N/A |
| IPR2019-00345 | Kinevac® | 6,803,046 | 19-Nov-18 | Shilpa Medicare Ltd; Maia Pharmaceuticals, Inc.; BS&H Investors LLC; Gland Pharma Ltd. | Bracco Diagnostics Inc. | Denied | N/A | N/A |
| IPR2019-00374 | | 9,610,345 | 30-Nov-18 | Intervet Inc. a/k/a Merck Animal Health | Boehringer Ingelheim Vetmedica, Inc. | Denied | N/A | N/A |
| IPR2019-00381 | | 9,669,087 | 30-Nov-18 | Intervet Inc. a/k/a Merck Animal Health | Boehringer Ingelheim Vetmedica, Inc. | Instituted | Pending | N/A |
| IPR2019-00400 | | 8,633,194 | 13-Dec-18 | Apotex Pharmaceuticals Holdings Inc.; Apotex Holdings, Inc.; Apotex Inc. | UCB Biopharma S.A. | Instituted | Pending | N/A |
| IPR2019-00406 | | 6,596,296 | 7-Dec-18 | Ethicon PR Holdings Unlimited Co.; OMJ Pharma., Inc.; Janssen Pharma.s; Ethicon Holding S.A.R.L. et al. | Board of Regents of the University of Texas System | N/A | Pending | N/A |
| IPR2019-00407 | | 7,033,603 | 7-Dec-18 | Ethicon PR Holdings Unlimited Co.; OMJ Pharma., Inc.; Janssen Pharma.s; Ethicon Holding S.A.R.L. et al. | Board of Regents of the University of Texas System | N/A | Pending | N/A |
| IPR2019-00442 | Dextenza® | 9,463,114 | 14-Dec-18 | Ocular Therapeutix | Mati Therapeutics, Inc. | Instituted | Pending | N/A |
| IPR2019-00448 | Dextenza® | 9,849,082 | 14-Dec-18 | Ocular Therapeutix | Mati Therapeutics, Inc. | Instituted | Pending | N/A |

| | | | | | | | | |
|---------------|-----------------|------------|-----------|--|-----------------------------------|------------|---------|-----|
| IPR2019-00449 | | 9,763,876 | 28-Jan-19 | Aquestive Therapeutics, Inc. | Hale Biopharma Ventures, LLC | Denied | N/A | N/A |
| IPR2019-00450 | | 9,763,876 | 29-Jan-19 | Aquestive Therapeutics, Inc. | Hale Biopharma Ventures, LLC | Denied | N/A | N/A |
| IPR2019-00451 | | 9,763,876 | 29-Jan-19 | Aquestive Therapeutics, Inc. | Hale Biopharma Ventures, LLC | Instituted | Pending | N/A |
| IPR2019-00459 | | 10,080,788 | 21-Dec-18 | CSL Behring GmbH and CSL Behring LLC | Shire ViroPharma Inc. | Denied | N/A | N/A |
| IPR2019-00488 | | 7,998,708 | 20-Dec-18 | QIAGEN North American Holdings Inc.; Qiagen N.V. | HandyLab, Inc. | Instituted | Pending | N/A |
| IPR2019-00490 | | 8,323,900 | 20-Dec-18 | QIAGEN North American Holdings Inc.; Qiagen N.V. | HandyLab, Inc. | Instituted | Pending | N/A |
| IPR2019-00554 | Onpattro™ | 8,058,069 | 9-Jan-19 | Moderna Therapeutics, Inc. | Arbutus Biopharma Corp. | Instituted | Pending | N/A |
| IPR2019-00565 | ddSEQ™ products | 9,695,468 | 15-Jan-19 | Bio-Rad Laboratories, Inc. | 10X Genomics, Inc. | Denied | N/A | N/A |
| IPR2019-00566 | ddSEQ™ products | 9,695,468 | 15-Jan-19 | Bio-Rad Laboratories, Inc. | 10X Genomics, Inc. | Denied | N/A | N/A |
| IPR2019-00567 | ddSEQ™ products | 9,689,024 | 15-Jan-19 | Bio-Rad Laboratories, Inc. | 10X Genomics, Inc. | Denied | N/A | N/A |
| IPR2019-00568 | ddSEQ™ products | 9,856,530 | 15-Jan-19 | Bio-Rad Laboratories, Inc. | 10X Genomics, Inc. | Denied | N/A | N/A |
| IPR2019-00577 | | 8,993,300 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00578 | | 8,455,232 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00579 | | 7,829,318 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00580 | | 7,312,063 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00581 | | 7,026,150 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00582 | | 6,451,572 | 23-Jan-19 | AB Enzymes, Inc.; Abitec Corp.; AB Vista, Inc.; et al. | Cornell Research Foundation, Inc. | Instituted | Pending | N/A |
| IPR2019-00634 | | 9,840,743 | 1-Feb-19 | Roche Holding Ltd.; Roche Holdins, Inc.; et al. | Guardant Health, Inc. | Instituted | Pending | N/A |
| IPR2019-00636 | | 9,902,992 | 1-Feb-19 | Roche Holding Ltd.; Roche Holdins, Inc.; et al. | Guardant Health, Inc. | Denied | N/A | N/A |
| IPR2019-00637 | | 9,902,992 | 1-Feb-19 | Roche Holding Ltd.; Roche Holdins, Inc.; et al. | Guardant Health, Inc. | Denied | N/A | N/A |
| IPR2019-00652 | | 9,834,822 | 1-Feb-19 | Roche Holding Ltd.; Roche Holdins, Inc.; et al. | Guardant Health, Inc. | Instituted | Pending | N/A |

| | | | | | | | | |
|---------------|---------|-----------|-----------|---|--|------------|---------|-----|
| IPR2019-00653 | | 9,834,822 | 1-Feb-19 | Roche Holding Ltd.; Roche Holdins, Inc.; et al. | Guardant Health, Inc. | Denied | N/A | N/A |
| IPR2019-00685 | Narcan® | 9,211,253 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | Instituted | Pending | N/A |
| IPR2019-00686 | Narcan® | 9,211,253 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | Denied | N/A | N/A |
| IPR2019-00687 | Narcan® | 9,211,253 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | Denied | N/A | N/A |
| IPR2019-00688 | Narcan® | 9,468,747 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00689 | Narcan® | 9,468,747 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00690 | Narcan® | 9,468,747 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00691 | Narcan® | 9,561,177 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | Denied | N/A | N/A |
| IPR2019-00692 | Narcan® | 9,561,177 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | Denied | N/A | N/A |

| | | | | | | | | |
|---------------|------------|-----------|-----------|---|--|------------|---------|-----|
| IPR2019-00693 | Narcan® | 9,561,177 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | Denied | N/A | N/A |
| IPR2019-00694 | Narcan® | 9,629,965 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00695 | Narcan® | 9,629,965 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00696 | Narcan® | 9,629,965 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc. | N/A | Pending | N/A |
| IPR2019-00697 | Narcan® | 9,775,838 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | N/A | Pending | N/A |
| IPR2019-00698 | Narcan® | 9,775,838 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | N/A | Pending | N/A |
| IPR2019-00699 | Narcan® | 9,775,838 | 19-Feb-19 | Burford Capital Ltd.; Nalox-1 Pharmaceuticals, LLC; BCIM PIII Holdings, LLC.; Burford Capital Ireland DAC; et al. | Opiant Pharmaceuticals, Inc.; Adapt Pharma Limited | N/A | Pending | N/A |
| IPR2019-00738 | | 8,409,862 | 25-Feb-19 | Laboratory Corporation (of America) | Quest Diagnostics Investments LLC | Instituted | Pending | N/A |
| IPR2019-00739 | Soliris® | 9,725,504 | 28-Feb-19 | Amgen Inc. | Alexion Pharmaceuticals | Instituted | Pending | N/A |
| IPR2019-00740 | Soliris® | 9,718,880 | 28-Feb-19 | Amgen Inc. | Alexion Pharmaceuticals | Instituted | Pending | N/A |
| IPR2019-00741 | Soliris® | 9,732,149 | 28-Feb-19 | Amgen Inc. | Alexion Pharmaceuticals | Instituted | Pending | N/A |
| IPR2019-00789 | Tecfidera® | 8,399,514 | 5-Mar-19 | Sawai USA, Inc.; Stason Pharmaceuticals, Inc. et al. | Biogen MA Inc. | N/A | Pending | N/A |

| | | | | | | | | | |
|---------------|---------------------|------------|-----------|--|---|---|-----|---------|-----|
| IPR2019-00791 | | 8,940,878 | 7-Mar-19 | Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals, Inc.; | Kashiv BioSciences, LLC | Amgen Inc. | N/A | Pending | N/A |
| IPR2019-00797 | | 9,643,997 | 7-Mar-19 | Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals, Inc.; | Kashiv BioSciences, LLC | Amgen Inc. | N/A | Pending | N/A |
| IPR2019-00865 | Imbruvica® | 9,795,604 | 21-Mar-19 | Lek Pharmaceuticals d.d. Sandoz, Inc. | | Pharmacyclics LLC | N/A | Pending | N/A |
| IPR2019-00867 | | 9,428,740 | 21-Mar-19 | Reactive Surfaces Ltd., LLP | | Toyota Motor Corp., Toyota Jidosha Kabushiki Kaisha | N/A | Pending | N/A |
| IPR2019-00971 | | 9,856,287 | 14-Apr-19 | Fresenius Kabi USA, LLC; Fresenius Kabi SwissBioSim GmbH | | Amgen, Inc. and Amgen Manufacturing Ltd. | N/A | Pending | N/A |
| IPR2019-01010 | | 10,035,973 | 1-May-19 | Danisco USA Inc. | | Novozymes A/S | N/A | Pending | N/A |
| IPR2019-01017 | Stevia | 9,243,273 | 25-Apr-19 | Conagen Inc.; SweeGen, Inc.; | Phyto Tech Corp. DBA Blue California | PureCircle USA Inc.; PureCircle Sdn Bhd | N/A | Pending | N/A |
| IPR2019-01021 | Epinephrine | 9,283,197 | 26-Apr-19 | Adamis Pharmaceuticals Corp. | | Belcher Pharmaceuticals, LLC | N/A | Pending | N/A |
| IPR2019-01027 | | 9,422,345 | 6-May-19 | Pfenex Inc. | | GlaxoSmithKline Biologicals S.A. | N/A | Pending | N/A |
| IPR2019-01028 | | 9,422,345 | 6-May-19 | Pfenex Inc. | | GlaxoSmithKline Biologicals S.A. | N/A | Pending | N/A |
| IPR2019-01086 | Eylea®; Zaltrap® | 5,688,688 | 14-May-19 | Regeneron Pharmaceuticals, Inc. | | Grifols Worldwide Operations Ltd; Novartis Vaccines and Diagnostics, Inc. | N/A | Pending | N/A |
| IPR2019-01095 | Aczone® | 9,517,219 | 7-Jun-19 | DPT Labs., Ltd.; Mylan N.V.; | Mylan, Inc.; et al. | Almirall, LLC | N/A | Pending | N/A |
| IPR2019-01141 | | 6,613,356 | 3-Jun-19 | New U Life Corporation | | VND Butyrate, LLC | N/A | Pending | N/A |
| IPR2019-01142 | | 8,431,549 | 14-Jun-19 | Pharmacosmos A/S | | American Regent, Inc. | N/A | Pending | N/A |
| IPR2019-01183 | | 9,643,997 | 8-Jun-19 | Fresenius Kabi SwissBioSim GmbH; Fresenius Kabi Deutschland GmbH; et al. | | Amgen Inc. | N/A | Pending | N/A |
| IPR2019-01201 | | 8,682,592 | 13-Jun-19 | illumina, Inc. | | Natera, Inc. | N/A | Pending | N/A |
| IPR2019-01392 | | 7,026,440 | 25-Jul-19 | NOF Corporation | | Nektar Therapeutics | N/A | Pending | N/A |
| IPR2019-01394 | | 7,026,440 | 25-Jul-19 | NOF Corporation | | Nektar Therapeutics | N/A | Pending | N/A |
| IPR2019-01395 | | 7,872,072 | 25-Jul-19 | NOF Corporation | | Nektar Therapeutics | N/A | Pending | N/A |
| IPR2019-01396 | | 8,809,453 | 25-Jul-19 | NOF Corporation | | Nektar Therapeutics | N/A | Pending | N/A |

| | | | | | | | | |
|---------------|------------|-----------|---|---|------------------------|---------|---------|-----|
| IPR2019-01397 | 9,187,569 | 25-Jul-19 | NOF Corporation | Nektar Therapeutics | N/A | Pending | N/A | |
| IPR2019-01398 | 8,273,833 | 25-Jul-19 | NOF Corporation | Nektar Therapeutics | N/A | Pending | N/A | |
| IPR2019-01446 | 9,913,853 | 1-Aug-19 | Nevakar, Inc.; Leiutis Pharmaceuticals Pvt. Ltd. | Cipla Limited | N/A | Pending | N/A | |
| IPR2019-01453 | 9,044,509 | 21-Aug-19 | Gilead Sciences, Inc. | USA, as represented by the Dept. of Health and Human Services | N/A | Pending | N/A | |
| IPR2019-01454 | 9,578,333 | 21-Aug-19 | Gilead Sciences, Inc. | USA, as represented by the Dept. of Health and Human Services | N/A | Pending | N/A | |
| IPR2019-01455 | 9,937,191 | 23-Aug-19 | Gilead Sciences, Inc. | USA, as represented by the Dept. of Health and Human Services | N/A | Pending | N/A | |
| IPR2019-01456 | 10,335,423 | 23-Aug-19 | Gilead Sciences, Inc. | USA, as represented by the Dept. of Health and Human Services | N/A | Pending | N/A | |
| IPR2019-01478 | 9,422,345 | 9-Aug-19 | Pfenex Inc. | GlaxoSmithKline Biologicals S.A. | N/A | Pending | N/A | |
| IPR2019-01480 | 8,715,669 | 12-Aug-19 | UCB, Inc. | NovImmune S.A. | N/A | Pending | N/A | |
| IPR2019-01481 | 8,771,697 | 12-Aug-19 | UCB, Inc. | NovImmune S.A. | N/A | Pending | N/A | |
| IPR2019-01493 | 7,998,708 | 15-Aug-19 | NeuMoDx Molecular, Inc.; Quigen N.V.; Qiagen North American Holdings Inc. | HandyLab, Inc. | N/A | Pending | N/A | |
| IPR2019-01494 | 8,323,900 | 15-Aug-19 | NeuMoDx Molecular, Inc.; Quigen N.V.; Qiagen North American Holdings Inc. | HandyLab, Inc. | N/A | Pending | N/A | |
| IPR2019-01497 | 9,723,842 | 15-Aug-19 | Sherwin-Williams Co. | Arch Chemicals, Inc. | N/A | Pending | N/A | |
| IPR2019-01498 | 9,723,842 | 15-Aug-19 | Sherwin-Williams Co. | Arch Chemicals, Inc. | N/A | Pending | N/A | |
| IPR2019-01499 | 9,717,250 | 15-Aug-19 | Sherwin-Williams Co. | Arch Chemicals, Inc. | N/A | Pending | N/A | |
| IPR2019-01505 | Juvéderm® | 8,450,475 | 3-Sep-19 | Prollenium US Inc.; Prollenium Medical Technologies, Inc. | Allergan Industrie SAS | N/A | Pending | N/A |
| IPR2019-01508 | Juvéderm® | 9,238,013 | 23-Aug-19 | Prollenium US Inc.; Prollenium Medical Technologies, Inc. | Allergan Industrie SAS | N/A | Pending | N/A |
| IPR2019-01509 | Juvéderm® | 9,358,322 | 3-Sep-19 | Prollenium US Inc.; Prollenium Medical Technologies, Inc. | Allergan Industrie SAS | N/A | Pending | N/A |